Dr. Hamilton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
250 25th Ave N
Suite 100
Nashville, TN 37203Phone+1 919-668-1748- Is this information wrong?
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2013
University of North Carolina HospitalsResidency, Internal Medicine, 2007 - 2009
University of North Carolina at Chapel Hill School of MedicineClass of 2007
Certifications & Licensure
TN State Medical License 2013 - 2025
NC State Medical License 2007 - 2014- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
- A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Start of enrollment: 2014 Feb 28
- A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Start of enrollment: 2013 Dec 31
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsAdjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results Fr...Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances Boyle, Javier Cortes, Hope S Rugo, Matthew P Goetz, Erika P Hamilton, Chiun-Sheng Huang, Elzbieta Senkus, Al...> ;Journal of Clinical Oncology. 2024 Mar 20
- A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma, Navid Hafez, Erika Hamilton, Sarina A Piha-Paul, Minal Barve, Trisha Wise-Draper,...> ;Clinical Therapeutics. 2024 Mar 1
- 2 citationsDiscovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A Boezio, Artemisa Bulku, Lucian DiPietro, Cary Fridrich, Adam Frost, Fabrizio Giord...> ;Cancer Discovery. 2024 Feb 8
- Join now to see all
Lectures
- Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC...ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- The Metastatic Breast Cancer Project: Engaging Patients, Advancing ResearchASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Join now to see all
Press Mentions
FDA Expands Enhertu Approval for Breast CancerMay 25th, 2022- ENHERTU® (Fam-Trastuzumab Deruxtecan-Nxki) Approved in the US for Patients with HER2-Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenMay 5th, 2022
- ENHERTU® Approved in the U.S. For Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenMay 5th, 2022
- Join now to see all
Hospital Affiliations
TriStar Centennial Medical CenterNashville, Tennessee
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
